openPR Logo
Press release

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026

05-20-2022 02:44 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market

"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights:

* Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026
* Role of FGFR Inhibitors in Cancer Therapy
* Global FGFR Market Assessment (US$) by Region and Cancer Type
Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq)
* Dosage and Drug Price Insight on Approved FGFR Inhibitors
* Comprehensive Clinical Trials Insight by Company, Country, Phase and Patient Segment: 53 Drugs in Trials

Download Report: https://www.kuickresearch.com/report-fibroblast-growth-factor-receptor-market-size-sales-companies-insight-growth-clinical-trials-balversa-erdafitinib-truseltiq-pemigatinib-pemazyre-infigratinib-human-fgfr1-fgfr2-fgfr3-pathway-cancer-mutation-fda-approved-fgfr-inhibitor

Recent breakthrough with respect to small molecule based therapy in the oncology segment has set up remarkable achievements in terms of improving the cancer survival rate. The FGFR inhibitors are considered as one of advanced anticancer therapy, which belongs to the class of receptor kinase inhibiting small molecules and now widely accepted for the treatment of various cancer types including bladder cancer, breast cancer, lung cancer gastric cancer, lymphoma, myeloma etc. In a short period of time, FGFR inhibitors has made its way through all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised.

The mutation or over expression of FGFR makes them ideal target for management of cancer and most of the researchers exploring the therapeutic potential of this class concluded the beneficial effects of this approach. Further, the FGFR alterations are also observed in rare cancers and hence this approach has potential to play a crucial role in the management of untreatable rare types of cancers. Currently, the market of FGFR inhibitors is at nascent stage, which is driven by the sales of 3 approved products of this class i.e. Balversa, Pemazyre and Truseltiq. Balversa is recommended for management of bladder cancer while Pemazyre and Truseltiq are recommended for the management of rare cancer termed as Cholangiocarcinoma. Many new drugs of this class are also believed to get orphan designation in upcoming years, which further boost the market size of this segment.

Balversa is expected to lead the market segment as its sales value is believed to increase exponentially after its approval in the leading regions including Europe and Japan. The estimated market size of FGFR inhibitor is about US$ 100 Million in year 2020 and it is believed to grow with CAGR of more than 80% during the next 6 years as most of the market related factors are indicating towards the increasing acceptance of this segment in near future. Further, US will lead FGFR market due to availability of huge cancer burden and leading pharmaceutical companies. The drug approval process is now simplified in US due to availability of all the three drugs of this class and hence most of the new FGFR inhibitors will first get approval in this region.

With an aim of improving the market penetrability and commercialization of FGFR inhibitors, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of developing companies, which will increase the market size of this novel segment in regions such as Asia-Pacific, Middle-East and Latin America. The leading pharmaceutical companies working in this sector are Amgen, Astem pharma, AstraZenca, Bayer, BMS, Incyte, Roche, Taiho, Janssen pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies.

"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to FGFR inhibitors market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for FGR inhibitors drugs.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366
https://www.kuickresearch.com/

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 here

News-ID: 2631495 • Views: 185

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026
"Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026" Report highlights: * Europe Biosimilars Market Opportunity: > USD 10 Billion * Dosage and Pricing insight On Approved Biosimilars * Biosimilars for Cancers Accounts for > 20% Market * Biosimilars for Diabetes Accounts for > 5% Market * Biosimilars Approval and Commercialization by Country * Insight On Biosimilar Clinical Trials By Company, Indication and Phase: > 100 Biosimilars * Insight On Commercially available Biosimilars in Market:

All 5 Releases


More Releases for FGFR

"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Anal …
Hepatocellular Carcinoma Disease Pipeline Drugs Assessment Overview: Hepatocellular Carcinoma is the most common primary tumour of liver. It is caused to the people who are having underlying liver diseases such as hepatitis B or C virus, Cirrhosis and non – alcoholic fatty liver disease. HCC does not cause any symptoms in the early stages of diseases. Some of the symptoms of HCC includes loss of appetite, weight loss, nausea and
Urothelial Carcinoma Treatment Market: Global Market Estimation, Dynamics, Regio …
Market Outline: Global Urothelial Carcinoma Treatment Market Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Download Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Out …
The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional
Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020
The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional